MedTrace Logo

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

NCT02899299 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 605

Last updated 2024-05-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

Conditions

Interventions

BIOLOGICAL

Nivolumab

BIOLOGICAL

Ipilimumab

DRUG

Pemetrexed

DRUG

Cisplatin

DRUG

Carboplatin

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-29
Primary Completion
2020-03-25
Completion
2023-04-28

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Chile
  • China
  • Colombia
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Russia
  • South Africa
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02899299 on ClinicalTrials.gov